GLP-1s and Sleep Apnea: the 9 Trials Behind the First Ever Approval

9 papers · each one re-checked on PubMed · last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Until recently, sleep apnea was treated with a machine. CPAP works well when worn, but roughly half of patients do not wear it, which left a large population with an effective therapy they could not tolerate and no alternative. The trials below closed that gap. SURMOUNT-OSA produced the December 2024 approval that made tirzepatide the first drug of any class licensed for the condition. Behind it sits a decade of groundwork: a liraglutide trial that first showed drug-driven weight loss lowers apnea severity, lifestyle trials that established roughly one fewer event per hour for every kilogram lost, and an imaging study that explained the mechanism. The list deliberately includes the small trial where CPAP improved a vascular marker and the drug did not, because 'as good as CPAP' is a claim the evidence does not yet support.

Ranked papers

#1SURMOUNT-OSA

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med · 2024

What it measured: Breathing interruptions per hour of sleep, after a year

The pivotal trial and the basis of the approval: 469 adults with moderate-to-severe apnea and obesity, run as two parallel studies, one in people not using CPAP and one in established users. Tirzepatide cut apnea-hypopnea events by 25.3 to 29.3 an hour against 5.3 to 5.5 on placebo at 52 weeks, about half or more of the starting index, with 17 to 20% weight loss. Daytime sleepiness, oxygen burden and sleep quality all improved. It made tirzepatide the first drug of any class approved for this condition.

PMID 38912654 ↗NCT05412004 ↗DOI 10.1056/NEJMoa2404881 ↗

#2SURMOUNT-OSA (secondary)

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial

Malhotra A, Bunck MC, Aronne LJ, et al. · Nat Med · 2026

What it measured: Blood pressure at week 48, plus overnight oxygen shortfall, inflammation and lipids

The prespecified cardiometabolic analysis of both SURMOUNT-OSA studies, with a post hoc analysis of what drove each change, and arguably where the clinical significance lives. Systolic blood pressure fell 7.9 and 4.3 mmHg more than on placebo in the two studies, and inflammation, insulin resistance and blood lipids improved. Better breathing itself, not only weight loss, explained part of the fall in inflammation, insulin resistance and triglycerides, while systolic pressure tracked weight. The authors conclude that both the apnea and the obesity need treating. Randomized CPAP trials have not shown fewer cardiovascular events, and no trial has yet tested whether these gains do.

PMID 41540105 ↗NCT05412004 ↗DOI 10.1038/s41591-025-04071-1 ↗

#3SCALE Sleep Apnea

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial

Blackman A, Foster GD, Zammit G, et al. · Int J Obes (Lond) · 2016

What it measured: Breathing interruptions per hour of sleep, after 32 weeks

The first dedicated trial of a GLP-1 in this condition, eight years before the approval: 359 adults with obesity and moderate-to-severe apnea who could not or would not use CPAP, on liraglutide or placebo for 32 weeks. Events fell 12.2 an hour against 6.1, with 5.7% weight loss. The effect was far smaller than tirzepatide later achieved, but it proved drug-driven weight loss lowers apnea severity independently of airway pressure, which is what made the later program worth funding.

PMID 27005405 ↗NCT01557166 ↗DOI 10.1038/ijo.2016.52 ↗

#4Sleep AHEAD

A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study

Foster GD, Borradaile KE, Sanders MH, et al. · Arch Intern Med · 2009

What it measured: Change in apnea-hypopnea index at 1 year

The pre-drug foundation, run inside a large diabetes trial: 264 adults randomized to intensive lifestyle intervention or education for a year. The intervention group lost 10.8 kg against 0.6 kg, and apnea events fell 9.7 an hour more than in controls. Its lasting contribution is the exchange rate of roughly one fewer event per hour for each kilogram lost, the yardstick every subsequent drug trial is implicitly measured against.

PMID 19786682 ↗NCT00194259 ↗DOI 10.1001/archinternmed.2009.266 ↗

#5Sleep AHEAD (4-year)

Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes

Kuna ST, Reboussin DM, Borradaile KE, et al. · Sleep · 2013

What it measured: AHI at 4 years

The four-year follow-up, addressing durability rather than effect. At year four the lifestyle group still weighed about 5 kg less than controls, had 7.7 fewer events per hour, and was five times as likely to be in remission (20.7% against 3.6%). Most of the one-year benefit held despite almost half the lost weight coming back, and part of it was independent of weight loss. The size of the change still tracked how much weight stayed off, which is why the withdrawal trials on the weight-loss lists matter here too.

PMID 23633746 ↗NCT00194259 ↗DOI 10.5665/sleep.2618 ↗

#6

Effect of Weight Loss on Upper Airway Anatomy and the Apnea-Hypopnea Index. The Importance of Tongue Fat

Wang SH, Keenan BT, Wiemken A, et al. · Am J Respir Crit Care Med · 2020

What it measured: Which tissues shrank on MRI, and whether breathing improved with them

The imaging study that explains the mechanism, and its finding is surprising. 67 adults with obesity and apnea had MRI scans before and after losing weight through intensive lifestyle change or bariatric surgery. Shrinking tongue fat tracked closely with fewer apnea events, still did after accounting for the total weight lost, and was the main upper-airway link between weight loss and better breathing. That reframes the disease around where fat sits rather than how much there is, and the authors suggest treatments that reduce tongue fat deserve consideration.

PMID 31918559 ↗DOI 10.1164/rccm.201903-0692OC ↗

#7

Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study

O'Donnell C, Crilly S, O'Mahony A, et al. · Ann Am Thorac Soc · 2024

What it measured: Insulin resistance at six months (registered); the paper reports vascular inflammation and plaque

The trial that keeps the claim in check. 30 adults with apnea and obesity were randomized for 24 weeks to CPAP, to liraglutide, or to the two together. CPAP cut apnea events far more than liraglutide alone (by about 45 an hour against 12). Liraglutide produced significant weight loss, yet only CPAP alone reduced inflammation in the aortic wall, along with better blood-vessel function, and unstable coronary plaque shrank on CPAP, alone or combined with the drug, while liraglutide by itself did not shrink it. It is a small proof-of-concept study, but it is direct evidence against assuming a drug can simply replace airway pressure, at least within six months.

PMID 38096106 ↗NCT04186494 ↗DOI 10.1513/AnnalsATS.202309-821OC ↗

#8STEP-HFpEF

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. · N Engl J Med · 2023

What it measured: How patients rated their heart-failure symptoms, plus weight, after a year

Included as adjacent context rather than an apnea trial. Heart failure with preserved ejection fraction and sleep apnea overlap heavily in obesity, and many people who qualified for the apnea trials would qualify here too. Semaglutide improved symptom scores by 7.8 points more than placebo across 529 patients, with 10.7 percentage points more weight loss. It suggests much of the cardiovascular benefit attributed to treating apnea may run through mechanisms these drugs address anyway.

PMID 37622681 ↗NCT04788511 ↗DOI 10.1056/NEJMoa2306963 ↗

#9

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis

Li M, Lin H, Yang Q, et al. · Sleep · 2025

What it measured: Breathing interruptions per hour, pooled across the randomized trials

The class-level pooling of six studies with 1,067 participants, giving about 9.5 fewer events per hour than the comparison groups and 11 kg of weight loss. Tirzepatide cut events far more than liraglutide (21.9 against 5.1 an hour), and people with obesity responded more than those without. Whether patients used CPAP made no difference to the effect, and neither did the length of follow-up. The studies varied widely, so treat the pooled figure as a rough average.

PMID 39626095 ↗DOI 10.1093/sleep/zsae280 ↗

About this list

Obesity medicine throws up the same handful of questions over and over, and we answer them with ranked lists anchored to the papers themselves. On 2026-11-07 every citation below was put back through PubMed. Where a trial has a registry entry, the card carries that link too, alongside the PubMed one.

Browse our full index of research lists or our long-form research articles.

See also: our tirzepatide overview page.